1
Enquiry period
with 28.02.2025 14:10
to 10.03.2025 13:00
2
Bidding period
with 10.03.2025 13:00
to 15.03.2025 11:00
3
Auction
17.03.2025 09:14
4
Evaluation
5
Bids have been evaluated
Status Active
Estimated value without VAT 13 500 MDL
Period of clarifications: 28 Feb 2025, 14:10 - 10 Mar 2025, 13:00
Submission of proposals: 10 Mar 2025, 13:00 - 15 Mar 2025, 11:00
Auction start date: 17 Mar 2025, 9:14

Supplier technical support:

(+373) 79999801

Sequencing Auxiliary Vials V14
Information about customer
Fiscal code/IDNO
Address
MD- 2028, MOLDOVA, mun.Chişinău, mun.Chişinău, str. Asachi Gh., 67A
Web site
---
The contact person
Full name
Dorina Lutenco
Contact phone
067493406
Purchase data
Date created
28 Feb 2025, 13:58
Date modified
28 Feb 2025, 14:10
Estimated value (without VAT)
13 500 MDL
The minimum downward of the price
135 MDL
Achizitii.md ID
21373491
Type of procedure
Open tender
Award criteria
The lowest price
Delivery address
MD- 2028, MOLDOVA, mun.Chişinău, mun.Chişinău, str. Asachi Gh., 67A
Contract period
28 Mar 2025 00:00 - 30 Dec 2025 02:00
List of positions
1)
Title
5.1. Sequencing Auxiliary Vials V14 CPV: 33600000-6 - Pharmaceutical products
Quantity: 5.0
Unit of measurement: Complet
Documents of the procurement procedure
duae.doc
Bidding Documents
-
28.02.25 14:10
ds bunuri_servicii.docx
Bidding Documents
-
28.02.25 14:10

The offers of the participants are available below, you can view the documents for the offers by clicking on the folder icon.

Based on the Working Group Decision, the selection of a winner requires:

1) Choose winner by clicking the button "Winner.”

2) Отправить в течении 3 дней на почту AAP bap@tender.gov.md отсканированное решение рабочей группы.

4) After choosing the winner, press the button: "Confirm"..

Qualification
Participant(s) name(s)
Normalized price
Status
1
Participant(s) name(s):

BIOGENTIX SOLUTIONS SRL

Normalized price: 13 500 MDL
Status: Awaiting
The history of the auction
View auction
Unfortunately, questions can be asked only during the "Active" period.
Clarifications